-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Scinai Immunotherapeutics Ltd. quarterly and annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and change rate from 2021 to 2024.
- Scinai Immunotherapeutics Ltd. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending 30 Jun 2023 was $3,611,000.
- Scinai Immunotherapeutics Ltd. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2024 was $4,796,000.
- Scinai Immunotherapeutics Ltd. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was $-6,233,000, a 8.44% decline from 2022.
- Scinai Immunotherapeutics Ltd. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was $-5,748,000, a 29.6% increase from 2021.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Change (%)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Change (%)